Risk Factors and Time to Occurrence of Genitourinary Toxicity After External Beam Radiotherapy for Prostate Cancer

被引：0
作者：
Kanemoto, Ayae [1 ]
Matsumoto, Yasuo [1 ]
Sugita, Tadashi [1 ]
Abe, Eisuke [3 ]
Yamana, Nobuko [3 ]
Saito, Toshihiro [2 ]
Kobayashi, Kazuhiro [2 ]
Yamazaki, Hiroyuki [2 ]
Bilim, Vladimir [2 ]
Tanikawa, Toshiki [2 ]
机构：
[1] Niigata Canc Ctr Hosp, Dept Radiat Oncol, 2-15-3 Kawagishi Cho, Niigata 9518566, Japan
[2] Niigata Canc Ctr Hosp, Dept Urol, 2-15-3 Kawagishi Cho, Niigata 9518566, Japan
[3] Niigata Univ, Med & Dent Hosp, Dept Radiat Oncol, Niigata, Japan
来源：
ANTICANCER RESEARCH | 2016年 / 36卷 / 05期
关键词：
Genitourinary toxicity; timing; risk factor; external-beam radiotherapy; prostate cancer; CONFORMAL RADIOTHERAPY; HORMONAL-THERAPY; DOSE-ESCALATION; TRIAL; OUTCOMES;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Aim: To retrospectively investigate the risk factors and time to occurrence of genitourinary (GU) toxicity after radiotherapy for localized prostate cancer. Patients and Methods: The study included 320 patients. The radiotherapy planning target volume encompassed the prostate with a 1-cm margin in the transverse plane and a 1-cm margin (Group A) or a 1.5-cm margin (Group B) in the longitudinal plane. Incidence rates, risk factors and time to occurrence of GU toxicity were evaluated. Results: After a median follow-up of 38.2 months, the rate of late grade 2-3 GU toxicity was 5.9% and the median interval was 18.3 months. The wider longitudinal margin was the single significant independent factor. The 2-year cumulative incidence rates of late grade >= 2 GU toxicity were 2.8% and 7.5% in Group A and B patients. Conclusion: A wider radiotherapy margin increased the risk of GU toxicity and led to earlier occurrence.
引用
收藏
页码：2441 / 2444
页数：4
相关论文
共 50 条
  • [21] Impact of image guidance on toxicity and tumour outcome in moderately hypofractionated external-beam radiotherapy for prostate cancer
    Jereczek-Fossa, B. A.
    Maucieri, A.
    Marvaso, G.
    Gandini, S.
    Fodor, C.
    Zerini, D.
    Riva, G.
    Alessandro, O.
    Surgo, A.
    Volpe, S.
    Fanetti, G.
    Arculeo, S.
    Zerella, M. A.
    Parisi, S.
    Maisonneuve, P.
    Vavassori, A.
    Cattani, F.
    Cambria, R.
    Garibaldi, C.
    Starzynska, A.
    Musi, G.
    De Cobelli, O.
    Ferro, M.
    Nole, F.
    Ciardo, D.
    Orecchia, R.
    MEDICAL ONCOLOGY, 2019, 36 (01)
  • [22] Risk factors for urethral stricture following external beam radiotherapy and HDR brachytherapy for prostate cancer
    Groom, Nicki
    Tsang, Yatman
    Lowe, Gerry
    Hoskin, Peter
    BRACHYTHERAPY, 2021, 20 (02) : 302 - 306
  • [23] Hospital burden of long-term genitourinary and gastrointestinal toxicity after radical radiotherapy for prostate cancer
    Redmond, Elaine J.
    Dolbec, Katelyn S.
    Fawaz, Aisling S.
    Flood, Hugh D.
    Girl, Subhasis K.
    SURGEON-JOURNAL OF THE ROYAL COLLEGES OF SURGEONS OF EDINBURGH AND IRELAND, 2018, 16 (03): : 171 - 175
  • [24] Treating intermediate-risk prostate cancer with hypofractionated external beam radiotherapy alone
    Faria, Sergio
    Dal Pra, Alan
    Cury, Fabio
    David, Marc
    Duclos, Marie
    Freeman, Carolyn R.
    Souhami, Luis
    RADIOTHERAPY AND ONCOLOGY, 2011, 101 (03) : 486 - 489
  • [25] Long Term Patient Reported Urinary Function Following External Beam Radiotherapy for Prostate Cancer
    Chin, S.
    Hayden, A. J.
    Gebski, V.
    Cross, S.
    Turner, S. L.
    CLINICAL ONCOLOGY, 2017, 29 (07) : 421 - 428
  • [26] Developments in External Beam Radiotherapy for Prostate Cancer
    Lumen, Nicolaas
    Ost, Piet
    Van Praet, Charles
    De Meerleer, Gert
    Villeirs, Geert
    Fonteyne, Valerie
    UROLOGY, 2013, 82 (01) : 5 - 10
  • [27] Hormonal Therapy or External-Beam Radiation With Brachytherapy and the Risk of Death From Prostate Cancer in Men With Intermediate Risk Prostate Cancer
    Rosenberg, Jonathan E.
    Chen, Ming-Hui
    Nguyen, Paul L.
    Braccioforte, Michelle H.
    Moran, Brian J.
    D'Amico, Anthony V.
    CLINICAL GENITOURINARY CANCER, 2012, 10 (01) : 21 - 25
  • [28] Low and high-dose-rate brachytherapy in combination with external beam radiotherapy for high risk prostate cancer
    Solodkiy, V. A.
    Pavlov, A. Yu
    Tsibulskii, A. D.
    Panshin, G. A.
    Dzidzaria, A. G.
    Mirzahanov, R., I
    ONKOUROLOGIYA, 2021, 17 (02): : 72 - 82
  • [29] A Systematic Review of the Efficacy and Toxicity of Brachytherapy Boost Combined with External Beam Radiotherapy for Nonmetastatic Prostate Cancer
    Slevin, Finbar
    Zattoni, Fabio
    Checcucci, Enrico
    Cumberbatch, Marcus G. K.
    Nacchia, Antonio
    Cornford, Philip
    Briers, Erik
    De Meerleer, Gert
    De Santis, Maria
    Eberli, Daniel
    Gandaglia, Giorgio
    Gillessen, Silke
    Grivas, Nikolaos
    Liew, Matthew
    Espinos, Estefania E. Linares
    Oldenburg, Jan
    Oprea-Lager, Daniela E.
    Ploussard, Guillaume
    Rouviere, Olivier
    Schoots, Ivo G.
    Smith, Emma Jane
    Stranne, Johan
    Tilki, Derya
    Smith, Catrin Tudur
    Van Den Bergh, Roderick C. N.
    Van Oort, Inge M.
    Wiegel, Thomas
    Yuan, Cathy Y.
    Van den Broeck, Thomas
    Henry, Ann M.
    EUROPEAN UROLOGY ONCOLOGY, 2024, 7 (04): : 677 - 696
  • [30] Anorectal dose-effect relations for late gastrointestinal toxicity following external beam radiotherapy for prostate cancer in the FLAME trial
    Groen, Veerle H.
    Zuithoff, Nicolaas P. A.
    van Schie, Marcel
    Monninkhof, Evelyn M.
    Kunze-Busch, Martina
    de Boer, Hans C. J.
    van Zyp, Jochem van der Voort
    Pos, Floris J.
    Smeenk, Robert Jan
    Haustermans, Karin
    Isebaert, Sofie
    Draulans, Cedric
    Depuydt, Tom
    Verkooijen, Helena M.
    van der Heide, Uulke A.
    Kerkmeijer, Linda G. W.
    RADIOTHERAPY AND ONCOLOGY, 2021, 162 : 98 - 104
12345